DETERMINATION: Phase III Trial of VRd ± ASCT With Ongoing Lenalidomide Maintenance in Patients With NDMM

June 3-7, 2022; Chicago, Illinois
In the phase III DETERMINATION trial, addition of ASCT to VRd induction with ongoing lenalidomide maintenance resulted in prolonged median PFS—but not OS—in newly diagnosed multiple myeloma.
Format: Microsoft PowerPoint (.ppt)
File Size: 300 KB
Released: June 10, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seagen

Related Content

Experts highlight key studies being presented at the 2022 ASH Annual Meeting in this commentary from Clinical Care Options (CCO)

Catherine M. Broome, MD John M. Burke, MD Corey Cutler, MD, MPH, FRCPC person default David Dingli, MD, PhD Amir T. Fathi, MD Shaji K. Kumar, MD Sagar Lonial, MD Peter Martin, MD Marshall Mazepa, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Allison Wheeler, MD, MSCI Amer Zeidan, MBBS, MPH Released: December 7, 2022

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Adolfo de la Fuente Burguera, MD
Program Director
Claudio Cerchione, MD, PhD Naval G. Daver, MD person default Pau Montesinos, MD, PhD Eytan M. Stein, MD
Released: December 1, 2022

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Claudio Cerchione, MD, PhD
Program Director
Naval G. Daver, MD Adolfo de la Fuente Burguera, MD Courtney DiNardo, MD, MSCE person default Giovanni Martinelli, MD
Released: November 30, 2022

Downloadable PDF resource as a helpful guide for the differences between covalent and emerging non-covalent BTK inhibitors in MCL, from Clinical Care Options (CCO)

Released: November 29, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings